Marshall M. Kaplan, MD; Ronald A. DeLellis, MD; Hubert J. Wolfe, MD
Treatment of primary biliary cirrhosis with ursodiol or colchicine may stabilize the disease or slow its rate of progression, but no reports of spontaneous or treatment-related remission have been published.
To determine whether primary biliary cirrhosis fully responds to low-dose oral methotrexate therapy.
Prospective case study with at least 6 years of observation.
Academic medical center.
5 of 19 patients with biopsy-proven precirrhotic primary biliary cirrhosis who had been ill for at least 1 year. Three of the 5 had not responded to colchicine or had responded only partially.
Oral methotrexate, 15 mg/wk in divided doses.
Symptoms, biochemical tests of liver function, and percutaneous liver biopsies. The latter were done at baseline, 1 to 2 years after initiation of methotrexate therapy, and then every 2 to 3 years during methotrexate therapy.
All 5 patients completely responded to medical treatment. Results of biochemical tests of liver function became normal, symptoms remitted, and serial liver biopsy specimens showed progressive histologic improvement. Biopsy specimens obtained after 5 to 12 years of treatment showed few signs of primary biliary cirrhosis and, in 3 patients, were close to normal. Five of the other 14 patients have responded biochemically and have shown histologic improvement; the other 9 have not responded to methotrexate therapy, have discontinued therapy, or have been lost to follow-up.
In some patients, primary biliary cirrhosis may remit in response to methotrexate alone or in combination with colchicine or ursodiol.
Kaplan MM, DeLellis RA, Wolfe HJ. Sustained Biochemical and Histologic Remission of Primary Biliary Cirrhosis in Response to Medical Treatment. Ann Intern Med. 1997;126:682–688. doi: 10.7326/0003-4819-126-9-199705010-00002
Download citation file:
Published: Ann Intern Med. 1997;126(9):682-688.
Biliary Disorders, Gastroenterology/Hepatology, Liver Disease.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use